• Mutation; HGNC; HGNC:583; APC; Simple; p.Ala697Val (c.2090C>T); ClinVar=VCV000216153; Zygosity=Unspecified (PubMed=24755471).
  
• Mutation; HGNC; HGNC:583; APC; Simple; p.Val2194Phefs*5 (c.6579delA); ClinVar=VCV001446272; Zygosity=Unspecified (PubMed=24755471).
  
• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=19378335; PubMed=24755471).
  
• Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Val290fs*8 (c.867_868insA); Zygosity=Unspecified (PubMed=24755471).
  

PubMed=1427983; DOI=10.1038/icb.1992.30
Whitehead R.H., Zhang H.H., Hayward I.P.
Retention of tissue-specific phenotype in a panel of colon carcinoma cell lines: relationship to clinical correlates.
Immunol. Cell Biol. 70:227-236(1992)

PubMed=19378335; DOI=10.1002/ijc.24289
Zhang H.-H., Walker F.E., Kiflemariam S., Whitehead R.H., Williams D., Phillips W.A., Mikeska T., Dobrovic A., Burgess A.W.
Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf.
Int. J. Cancer 125:297-307(2009)

PubMed=23458625; DOI=10.1021/pr3010869
Fanayan S., Smith J.T., Lee L.Y., Yan F.-F., Snyder M.P., Hancock W.S., Nice E.
Proteogenomic analysis of human colon carcinoma cell lines LIM1215, LIM1899, and LIM2405.
J. Proteome Res. 12:1732-1742(2013)

PubMed=24295106; DOI=10.1021/pr400861m
Sethi M.K., Thaysen-Andersen M., Smith J.T., Baker M.S., Packer N.H., Hancock W.S., Fanayan S.
Comparative N-glycan profiling of colorectal cancer cell lines reveals unique bisecting GlcNAc and alpha-2,3-linked sialic acid determinants are associated with membrane proteins of the more metastatic/aggressive cell lines.
J. Proteome Res. 13:277-288(2014)

PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013
Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.
Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.
Cancer Res. 74:3238-3247(2014)

PubMed=25926053; DOI=10.1038/ncomms8002
Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
Nat. Commun. 6:7002.1-7002.10(2015)

PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457
Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E., Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R., Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.
Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.
Clin. Cancer Res. 21:3695-3704(2015)